Yifan Pharmaceuticals (002019.SZ): Clinical trials of human growth hormone injection solution approved.

Zhitan Financial News APP, Yifan Medicine (002019.SZ) announced that its wholly-owned subsidiary Yifan Medicine (Shanghai) Co., Ltd. recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The drug is named: Recombinant Human Growth Hormone Injection. The National Medical Products Administration has approved the conduct of clinical trials in accordance with the requirements for biosimilar drugs.